393 related articles for article (PubMed ID: 18397178)
1. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab induction in kidney transplantation.
Huang E; Cho YW; Shah T; Peng A; Hayashi R; Bunnapradist S
Clin Transpl; 2005; ():343-54. PubMed ID: 17424750
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation.
Pascual J; Mezrich JD; Djamali A; Leverson G; Chin LT; Torrealba J; Bloom D; Voss B; Becker BN; Knechtle SJ; Sollinger HW; Pirsch JD; Samaniego MD
Transplantation; 2007 Jun; 83(11):1429-34. PubMed ID: 17565315
[TBL] [Abstract][Full Text] [Related]
10. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
13. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
14. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab induction in renal transplantation.
Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
[TBL] [Abstract][Full Text] [Related]
17. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab and minimization immunotherapy in kidney transplantation: long-term results of comparison with rabbit anti-thymocyte globulin and standard triple maintenance therapy.
Zachariah M; Nader ND; Brar J; Singh N; Venuto R; Patel S; Said M; Laftavi MR; Pankewycz O
Transplant Proc; 2014; 46(1):94-100. PubMed ID: 24507032
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
Peng W; Liu G; Xie W; Huang H; Wu J; Shou Z; Chen J
Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071
[TBL] [Abstract][Full Text] [Related]
20. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
Saull HE; Enderby CY; Gonwa TA; Wadei HM
Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
